BindingDB

null

SMILES [#6]-c1nc2sccn2c(=O)c1-[#6]-[#6]-[#7]-1-[#6]-[#6]\[#6](-[#6]-[#6]-1)=[#6](\c1ccc(F)cc1)-c1ccc(F)cc1

InChI Key InChIKey=JUQLTPCYUFPYKE-UHFFFAOYSA-N

PDB links: 1 PDB ID matches this monomer.

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 50001775

5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Roche Bioscience

Curated by PDSP K_i Database

BDBM50001775((ritanserin)6-(2-{4-[Bis-(4-fluoro-phenyl)-methyle...)copy SMILEScopy InChI

Ki: 0.25nMMore data for this Ligand-Target Pair

PDB MMDB Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2NV9GSNPubMed

5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Roche Bioscience

Curated by PDSP K_i Database

BDBM50001775((ritanserin)6-(2-{4-[Bis-(4-fluoro-phenyl)-methyle...)copy SMILEScopy InChI

Ki: 0.25nMMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2NV9GSNPubMed

5-hydroxytryptamine receptor 2A(Rattus norvegicus (rat))
Roche Bioscience

Curated by PDSP K_i Database

BDBM50001775((ritanserin)6-(2-{4-[Bis-(4-fluoro-phenyl)-methyle...)copy SMILEScopy InChI

Ki: 0.290nMMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2NV9GSNPubMed

5-hydroxytryptamine receptor 2C(Rattus norvegicus (Rat))
Roche Bioscience

Curated by PDSP K_i Database

BDBM50001775((ritanserin)6-(2-{4-[Bis-(4-fluoro-phenyl)-methyle...)copy SMILEScopy InChI

Ki: 2.69nMMore data for this Ligand-Target Pair

PDB KEGG
UniProtKB/SwissProt
DrugBank GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2NV9GSNPubMed

5-hydroxytryptamine receptor 2B(Homo sapiens (Human))
Roche Bioscience

Curated by PDSP K_i Database

BDBM50001775((ritanserin)6-(2-{4-[Bis-(4-fluoro-phenyl)-methyle...)copy SMILEScopy InChI

Ki: 6.45nMMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2NV9GSNPubMed

Targets 22 ▿
- 5-hydroxytryptamine receptor 2A 22
- 5-hydroxytryptamine receptor 7 21
- 5-hydroxytryptamine receptor 2C 19
- 5-hydroxytryptamine receptor 2B 15
- D(2) dopamine receptor 13
- 5-hydroxytryptamine receptor 6 9
- Serotonin 2 (5-HT2) receptor 8
- Alpha-1A/Alpha-1B/Alpha-1D adrenergic receptor 5
- Alpha-1A adrenergic receptor 4
- 5-hydroxytryptamine receptor 1A 3
- Diacylglycerol kinase alpha 2
- 5-hydroxytryptamine receptor 1B 2
- 5-hydroxytryptamine receptor 1A/1B/1D/1F 1
- Alpha-2C adrenergic receptor 1
- D(4) dopamine receptor 1
- D(3) dopamine receptor 1
- 5-hydroxytryptamine receptor 2A/2B/2C 1
- Histamine H1 receptor 1
- D(1A) dopamine receptor 1
- 5-hydroxytryptamine receptor 3A 1
- Ubiquitin-conjugating enzyme E2 N 1
- 5-hydroxytryptamine receptor 1D 1
- ...
Publications 46 ▿
- Neuropharmacology 33: 275-317 (1994) 10
- J Med Chem 34: 2477-83 (1991) 8
- NIDA Res Monogr 178: 440-66 (1998) 7
- Br J Pharmacol 115: 622-8 (1995) 7
- Eur J Med Chem 164: 378-390 (2019) 6
- Br J Pharmacol 130: 692-8 (2000) 5
- Neuropharmacology 36: 621-9 (1997) 5
- J Pharmacol Exp Ther 317: 910-8 (2006) 5
- Trends Pharmacol Sci 18: 104-7 (1997) 4
- J Med Chem 35: 552-8 (1992) 4
- J Med Chem 39: 3723-38 (1996) 3
- Proc Natl Acad Sci U S A 83: 8784-8 (1986) 3
- Naunyn Schmiedebergs Arch Pharmacol 370: 114-23 (2004) 3
- J Med Chem 36: 2761-70 (1993) 3
- Mol Psychiatry 3: 123-34 (1998) 3
- Naunyn Schmiedebergs Arch Pharmacol 356: 328-34 (1997) 3
- J Med Chem 31: 2247-56 (1989) 3
- J Med Chem 35: 4813-22 (1993) 3
- J Med Chem 35: 4823-31 (1993) 3
- J Med Chem 46: 2795-812 (2003) 2
- J Pharmacol Exp Ther 276: 720-7 (1996) 2
- Br J Pharmacol 126: 179-88 (1999) 2
- Neuron 11: 449-58 (1993) 2
- Naunyn Schmiedebergs Arch Pharmacol 357: 17-24 (1998) 2
- J Pharmacol Exp Ther 260: 1361-5 (1992) 2
- J Med Chem 36: 3073-6 (1993) 2
- Bioorg Med Chem 16: 4661-9 (2008) 2
- J Med Chem 36: 1488-95 (1993) 2
- Naunyn Schmiedebergs Arch Pharmacol 365: 242-52 (2002) 2
- J Biol Chem 268: 18200-4 (1993) 2
- Neuropharmacology 36: 713-20 (1997) 2
- Br J Pharmacol 115: 107-16 (1995) 2
- J Biol Chem 268: 23422-6 (1993) 2
- Mol Pharmacol 43: 320-7 (1993) 2
- Psychopharmacology (Berl) 124: 57-73 (1996) 1
- J Pharmacol Exp Ther 262: 759-68 (1992) 1
- Bioorg Med Chem Lett 4: 415-420 (1994) 1
- PubChem Bioassay (2011) 1
- Bioorg Med Chem Lett 26: 3216-3219 (2016) 1
- J Med Chem 46: 5638-50 (2003) 1
- J Med Chem 40: 586-93 (1997) 1
- Bioorg Med Chem Lett 10: 1097-100 (2000) 1
- J Med Chem 37: 950-62 (1994) 1
- J Pharmacol Exp Ther 247: 169-73 (1988) 1
- Br J Pharmacol 127: 1075-82 (1999) 1
- J Neurochem 66: 47-56 (1996) 1
Institutions 35 ▿
- [H. Lundbeck A/S] 16
- [University of Alberta, Roche Bioscience] 10
- [University of Alberta, Roche Bioscience] 10
- [Syntex Discovery Research] 9
- [Centre de Recherches de Vitry Alfortville Rh£ne-Poulenc Rorer] 8
- [SRI International] 7
- [University of Piemonte Orientale] 6
- [Friedrich-Schiller-University Jena, ACADIA Pharmaceuticals Inc.] 5
- [Friedrich-Schiller-University Jena, ACADIA Pharmaceuticals Inc.] 5
- [National Institute of Neurological Disorders and Stroke, R. W. Johnson Pharmaceutical Research Institute, Scios Nova Inc.] 4
- [National Institute of Neurological Disorders and Stroke, R. W. Johnson Pharmaceutical Research Institute, Scios Nova Inc.] 4
- [National Institute of Neurological Disorders and Stroke, R. W. Johnson Pharmaceutical Research Institute, Scios Nova Inc.] 4
- [The Oregon Health Sciences University, Vernalis Research, Rhône-Poulenc Rorer, University of Toronto] 3
- [The Oregon Health Sciences University, Vernalis Research, Rhône-Poulenc Rorer, University of Toronto] 3
- [The Oregon Health Sciences University, Vernalis Research, Rhône-Poulenc Rorer, University of Toronto] 3
- [The Oregon Health Sciences University, Vernalis Research, Rhône-Poulenc Rorer, University of Toronto] 3
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Lilly Research Laboratories, Monash University, F. Hoffmann-La Roche Ltd., The Scripps Research Institute, Purdue University, Virginia Commonwealth University, Synaptic Pharmaceutical Corporation, Institut de Recherches Servier, Stanford University , Eli Lilly and Company, Universidad Complutense] 2
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
- [Burnham Center for Chemical Genomics, TBA, University of Washington, Sanofi Recherche, Vanderbilt University, Janssen Research Foundation, FAES, S.A., City University Of New York] 1
Affinity: 0.010 to 2.0E+4 nM▿
- Ki 107
- IC50 26
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1